Literature DB >> 15924336

Estrogen effects on tubulin expression and taxane mediated cytotoxicity in prostate cancer cells.

R Bruce Montgomery1, Michael Bonham, Peter S Nelson, Jonathan Grim, Ekram Makary, Robert Vessella, William L Stahl.   

Abstract

BACKGROUND: The present study was designed to determine if estrogens change microtubule polymerization and modulate cell cycle progression in vitro, related to modulation of tubulin expression and to determine if estrogens had antagonistic or synergistic effects with microtubule active agents.
METHODS: cDNA array analysis of LNCaP cells treated with the estrogens, estradiol, estrone, diethylstilbestrol (DES), and 2-methoxyestradiol (2-ME) was carried out and the results confirmed by PCR and Western blotting. Microtubule arrays in cells treated with estrogens were assessed using indirect immunofluorescence. The effects of combining estrogens with taxane was assessed by MTT assay and flow cytometry for cell cycle kinetics. Human prostate cancer xenografts were treated with DES and docetaxel to assess the effects of combining estrogens and taxane in vivo.
RESULTS: Treatment of LNCaP cells with DES and 2-ME suppressed transcripts and protein for beta-tubulin isotype IVa. This effect on tubulin synthesis was not blocked by estrogen or androgen receptor modulators. Other estrogens had no effect on beta-tubulin expression. 2-ME and DES decreased the density of microtubules. The administration of DES or 2-ME with paclitaxel enhanced cytotoxicity and G(2)-M arrest in vitro. DES enhanced tumor suppression in a human prostate cancer xenograft model when combined with the taxane docetaxel.
CONCLUSION: The use of DES and 2-ME enhances the effects of taxanes and may be a novel and important means of increasing therapeutic efficacy of cytotoxic chemotherapy against prostate carcinoma. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15924336     DOI: 10.1002/pros.20246

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  8 in total

Review 1.  Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies.

Authors:  Cameron M Armstrong; Allen C Gao
Journal:  Am J Clin Exp Urol       Date:  2015-08-08

2.  Inhibition of androgen-independent prostate cancer by estrogenic compounds is associated with increased expression of immune-related genes.

Authors:  Ilsa M Coleman; Jeffrey A Kiefer; Lisha G Brown; Tiffany E Pitts; Peter S Nelson; Kristen D Brubaker; Robert L Vessella; Eva Corey
Journal:  Neoplasia       Date:  2006-10       Impact factor: 5.715

3.  Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer.

Authors:  Meng-Lei Zhu; Craig M Horbinski; Mark Garzotto; David Z Qian; Tomasz M Beer; Natasha Kyprianou
Journal:  Cancer Res       Date:  2010-08-31       Impact factor: 12.701

4.  Inhibition of XO or NOX attenuates diethylstilbestrol-induced endothelial nitric oxide deficiency without affecting its effects on LNCaP cell invasion and apoptosis.

Authors:  Ji-Youn Youn; Andrew Nguyen; Hua Cai
Journal:  Clin Sci (Lond)       Date:  2012-10       Impact factor: 6.124

Review 5.  Improving the outcome of patients with castration-resistant prostate cancer through rational drug development.

Authors:  G Attard; D Sarker; A Reid; R Molife; C Parker; J S de Bono
Journal:  Br J Cancer       Date:  2006-09-19       Impact factor: 7.640

6.  Elevated prx1 provides resistance to docetaxel, but is not associated with predictive significance in lung cancer.

Authors:  Ki Eun Hwang; Chul Park; Chang Hwan Seol; Yu Ri Hwang; June Seong Hwang; Jae Wan Jung; Keum Ha Choi; Eun Taik Jeong; Hak Ryul Kim
Journal:  Tuberc Respir Dis (Seoul)       Date:  2013-08-30

7.  Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer.

Authors:  Cameron M Armstrong; Allen C Gao
Journal:  Asian J Urol       Date:  2016-08-22

8.  Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer.

Authors:  A Omlin; C J Pezaro; S Zaidi; D Lorente; D Mukherji; D Bianchini; R Ferraldeschi; S Sandhu; D Dearnaley; C Parker; N Van As; J S de Bono; G Attard
Journal:  Br J Cancer       Date:  2013-08-08       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.